Invitation: 12th St. Gallen International Breast Cancer Conference, March 16-19, 2011

ST. GALLEN, Switzerland, January 11, 2011 - This bi-annual conference will highlight meaningful advances
concerning treatment of Early Breast Cancer (EBC). The conference will build
up on earlier diagnostic and therapeutic recommendations and thereafter
provide written guidelines for the international community. Breast cancer
specialists from all over the world are awaiting these new guidelines.

The highlights:

1. Until recently, patients with HER2 positive breast cancer
had to face inferior prognosis. Now, a part of these patients may be cured
from their disease.

2. New therapeutics (PARP inhibitors) will be used in the
clinical setting, especially in patients with tripple-negative breast cancer.

3. Bisphosphonates are used in treatment of bone metastases,
but they are increasingly expected to prevent disease relaps.

4. Advancements in molecular cancer diagnostics allow
individual, targeted treatment. This means less treatment burden. Fewer women
need chemotherapy - but rather antihormonal treatment.

Concluding highlights: Medical progress and increasingly
complex and individual diagnostic and therapeutic strategies require cancer
care in certified breast centers, says Prof. Dr. med. Hans-Jorg Senn,
Chairperson of the St. Gallen Breast Cancer Conference and partner at the
tumor- and breast center ZeTuP in St. Gallen.

The international conference with 4500-5000 specialists from
all over the world is organized by the Foundation St. Gallen Oncology
Conferences (SONK). This unique event is one of the most important worldwide
for two reasons:

1. Recommendations for diagnoses and treatment of EBC are
developed by an open consensus-process: a panel of over 40 international
breast cancer experts discusses topical issues. This process takes place in
front of thousands of conference participants during several hours. The
consensus panel is then editing the internationally accepted guidelines,
which are published two months later.

2. The Consensus Conference and its recommendations are based
on scientific evidence and on patient-orientated care and are independent
from politics and pharmaceutical industry.

Important: To speed up free access for media representatives,
pre-registration is required (online-registration and further Information:
www.oncoconferences.ch).

Sender: Prof. Dr. med. Hans-Jorg Senn, Chairperson, St. Gallen,
Switzerland

Information: Dr.med. Thomas Ferber, media representative in
charge, info@oncoletter.ch Conference Manager: Judith Eberhardt:
judith.eberhardt@oncoconferences.ch , +41-71-243-02-81

Information: Dr.med. Thomas Ferber, media representative in charge, info at oncoletter.ch Conference Manager: Judith Eberhardt: judith.eberhardt at oncoconferences.ch , +41-71-243-02-81